Evaluate Vantage Homepage
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Spero proves a canny dealmaker – again
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
Medtech
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
TCT 2022 – Edwards tries to Clasp an opportunity
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Company Events
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Prometheus takes on Pfizer in inflammatory bowel diseases
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Interviews
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
T3D puts a bet on Alzheibetes
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.